Videos

Enhertu with Perjeta nearly doubled progression-free survival versus standard treatment in metastatic HER2-positive breast cancer, study shows.

The VERIFY trial explores rusfertide to manage polycythemia vera without causing iron deficiency symptoms, Dr. Aaron Gerds explained.

Michelle Kirschner discusses the how patients can foster a strong network of supporters from diagnosis through survivorship.

It is important to understand why it is vital that patients and survivors of cancer take steps to reduce the body’s burden both before and after treatment.

Adding subcutaneous sasanlimab to BCG improved recurrence-free survival in non–muscle-invasive bladder cancer, according to Dr. Petros Grivas.

Natalie Schnaitmann discusses urgent supportive care gaps younger women with cancer encounter, and how they affect long-term quality of life.

New or persistent acid reflux, especially after age 50, may mean higher risk for esophageal cancer, particularly in people with other known risk factors.

Dr. Massimo Cristofanilli discusses the early use of camizestrant with a CDK4/6 inhibitor to target ESR1 mutations, as it may improve outcomes in metastatic breast cancer.

Dr. Sarah Sammons discusses side effects associated with RLY-2608, and how it effects patients with HR-positive, HER2-negative advanced breast cancer.

Dr. Alexander Chehrazi-Raffle discusses findings from the phase 3 TiNivo-2 trial, designed to evaluate treatment with Fotivda in patients with metastatic renal cell carcinoma.

Dr. Jared Weiss sat down for an interview to discuss a trial evaluating JNJ-1900, an immune-stimulating radiation sensitizer, in those with lung cancer.

Minimally invasive screening methods offer a more accessible, cost-effective way to detect Barrett’s esophagus early and help prevent esophageal cancer.

A variant in the IL-7 gene may predict which patients with kidney cancer are more likely to experience side effects from immunotherapy.

Dr. Tiziano Barbui explains how excess blood cell production in certain myeloproliferative neoplasms can impair circulation and why treatments like phlebotomy are used.

IDH inhibitors, now FDA approved for lower-grade gliomas, yield fewer side effects than chemotherapy, said Dr. Ryan Merrell.

Dr. Andrew M. Evens discusses some of the recent research advancements in AYA lymphoma care that have emerged through clinical trials and initiatives.

Avoiding smoking, eating a high-fiber diet and routine screenings are key to reducing the risk of recurrence in colorectal or anal cancer.

Dr. Shirley D’Sa discusses how treatment strategies for WM have evolved over the course of her career.

Arterial thrombosis may occur years before cancer diagnosis, suggesting it could be a risk factor, according to Dr. Tiziano Barbui.

Proton therapy may reduce urinary, bowel and sexual side effects in prostate cancer by minimizing radiation exposure to healthy tissue, per Dr. Curtiland Deville Jr.

Carly Stafford Dixon, discusses how she approached fertility preservation after her diagnosis of primary mediastinal b-cell lymphoma, a rare blood cancer.

Dr. Suresh Ramalingam discussed how the LAURA findings support the role of Tagrisso as a backbone therapy across multiple settings in EGFR-mutated NSCLC.

Dr. Daniel P. Petrylak discusses the different types of bladder cancer and how treatment options may vary based on disease stage and type.

Dr. Kara Kelly discusses specific long-term health considerations that AYA survivors of lymphoma should be aware of to best prepare for survivorship.

Robotic and minimally invasive kidney cancer surgery may reduce pain, shorten recovery time and preserve kidney function, according to Dr. Armine Smith.

Panelists discuss how a multidisciplinary team approach to patient education and medication management is crucial for ensuring adherence and optimal outcomes with oral medications like elacestrant

Panelists discuss how real-world studies have shown improved outcomes with elacestrant compared with the original EMERALD trial data, demonstrating that proper patient selection leads to better treatment responses.

Researchers followed patients for years and found that the risk of dying from prostate cancer depended on how aggressive the cancer was at diagnosis.

Building long-term trust with providers can help patients with MPNs feel supported, encourage them to speak up and navigate care with confidence.

The field of radiation oncology has advanced in brain cancer treatment with precise therapeutic approaches including proton and carbon therapy.